Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology

Ashwani K. Singal, Habeeb Salameh, Yong Fang Kuo, Russell H. Wiesner

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation is increasing. Data are scanty on outcomes of SLK transplants for liver disease etiology. METHODS: Outcomes for liver and kidney grafts and patients survival at 5 years were compared for liver disease etiology among adults receiving SLK during 2002 and 2011 in the United States. Cox regression analysis models were built to determine the independent impact of liver disease etiology on outcomes. RESULTS: A total of 2,606 patients (mean age 53 years, 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alcoholic liver disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohepatitis (NASH) (n=221), hepatitis B virus (HBV) (n=98), and hepatocellular carcinoma (HCC) (n=249). HCV and NASH+CC contributed to about 44% and 9%, respectively, of all SLK transplants in 2002. Corresponding figures in 2011 were 34% and 22%, respectively. Compared to PBC, 5-year outcomes were worse for NASH, HCV, and HCC for liver graft (72%, 66%, and 72% vs. 82%; hazard ratio, HR: 2.5-3.1), kidney graft (71%, 65%, and 71% vs. 80%; HR: 2.3-2.8), and patient survival (74%, 69%, and 69% vs. 82%; HR: 2.4-2.7). Follow-up renal function assessed at 1, 3, and 5 years showed poor renal function among patients receiving SLK for HCV, NASH, CC, and HBV. CONCLUSIONS: Frequency of SLK transplants is increasing among NASH patients. Overall graft and patient outcomes are good. However, SLK for NASH, HCV, and HCC do worse. Strategies are needed to improve outcomes for SLK in HCV and NASH patients.

Original languageEnglish (US)
Pages (from-to)216-221
Number of pages6
JournalTransplantation
Volume98
Issue number2
DOIs
StatePublished - Jul 27 2014

Fingerprint

Liver Diseases
Transplants
Kidney
Liver
Hepacivirus
Hepatocellular Carcinoma
Hepatitis B virus
Sclerosing Cholangitis
Alcoholic Liver Diseases
Biliary Liver Cirrhosis
Graft Survival
Non-alcoholic Fatty Liver Disease
Liver Transplantation
Kidney Transplantation
Regression Analysis
Alcohols
Survival

Keywords

  • Graft survival
  • Liver transplantation
  • Mortality
  • SLK
  • UNOS

ASJC Scopus subject areas

  • Transplantation

Cite this

Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. / Singal, Ashwani K.; Salameh, Habeeb; Kuo, Yong Fang; Wiesner, Russell H.

In: Transplantation, Vol. 98, No. 2, 27.07.2014, p. 216-221.

Research output: Contribution to journalArticle

Singal, Ashwani K. ; Salameh, Habeeb ; Kuo, Yong Fang ; Wiesner, Russell H. / Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. In: Transplantation. 2014 ; Vol. 98, No. 2. pp. 216-221.
@article{83f116168a9d48099720ddc015456003,
title = "Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology",
abstract = "BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation is increasing. Data are scanty on outcomes of SLK transplants for liver disease etiology. METHODS: Outcomes for liver and kidney grafts and patients survival at 5 years were compared for liver disease etiology among adults receiving SLK during 2002 and 2011 in the United States. Cox regression analysis models were built to determine the independent impact of liver disease etiology on outcomes. RESULTS: A total of 2,606 patients (mean age 53 years, 69{\%} males, 55{\%} Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alcoholic liver disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohepatitis (NASH) (n=221), hepatitis B virus (HBV) (n=98), and hepatocellular carcinoma (HCC) (n=249). HCV and NASH+CC contributed to about 44{\%} and 9{\%}, respectively, of all SLK transplants in 2002. Corresponding figures in 2011 were 34{\%} and 22{\%}, respectively. Compared to PBC, 5-year outcomes were worse for NASH, HCV, and HCC for liver graft (72{\%}, 66{\%}, and 72{\%} vs. 82{\%}; hazard ratio, HR: 2.5-3.1), kidney graft (71{\%}, 65{\%}, and 71{\%} vs. 80{\%}; HR: 2.3-2.8), and patient survival (74{\%}, 69{\%}, and 69{\%} vs. 82{\%}; HR: 2.4-2.7). Follow-up renal function assessed at 1, 3, and 5 years showed poor renal function among patients receiving SLK for HCV, NASH, CC, and HBV. CONCLUSIONS: Frequency of SLK transplants is increasing among NASH patients. Overall graft and patient outcomes are good. However, SLK for NASH, HCV, and HCC do worse. Strategies are needed to improve outcomes for SLK in HCV and NASH patients.",
keywords = "Graft survival, Liver transplantation, Mortality, SLK, UNOS",
author = "Singal, {Ashwani K.} and Habeeb Salameh and Kuo, {Yong Fang} and Wiesner, {Russell H.}",
year = "2014",
month = "7",
day = "27",
doi = "10.1097/TP.0000000000000048",
language = "English (US)",
volume = "98",
pages = "216--221",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology

AU - Singal, Ashwani K.

AU - Salameh, Habeeb

AU - Kuo, Yong Fang

AU - Wiesner, Russell H.

PY - 2014/7/27

Y1 - 2014/7/27

N2 - BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation is increasing. Data are scanty on outcomes of SLK transplants for liver disease etiology. METHODS: Outcomes for liver and kidney grafts and patients survival at 5 years were compared for liver disease etiology among adults receiving SLK during 2002 and 2011 in the United States. Cox regression analysis models were built to determine the independent impact of liver disease etiology on outcomes. RESULTS: A total of 2,606 patients (mean age 53 years, 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alcoholic liver disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohepatitis (NASH) (n=221), hepatitis B virus (HBV) (n=98), and hepatocellular carcinoma (HCC) (n=249). HCV and NASH+CC contributed to about 44% and 9%, respectively, of all SLK transplants in 2002. Corresponding figures in 2011 were 34% and 22%, respectively. Compared to PBC, 5-year outcomes were worse for NASH, HCV, and HCC for liver graft (72%, 66%, and 72% vs. 82%; hazard ratio, HR: 2.5-3.1), kidney graft (71%, 65%, and 71% vs. 80%; HR: 2.3-2.8), and patient survival (74%, 69%, and 69% vs. 82%; HR: 2.4-2.7). Follow-up renal function assessed at 1, 3, and 5 years showed poor renal function among patients receiving SLK for HCV, NASH, CC, and HBV. CONCLUSIONS: Frequency of SLK transplants is increasing among NASH patients. Overall graft and patient outcomes are good. However, SLK for NASH, HCV, and HCC do worse. Strategies are needed to improve outcomes for SLK in HCV and NASH patients.

AB - BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation is increasing. Data are scanty on outcomes of SLK transplants for liver disease etiology. METHODS: Outcomes for liver and kidney grafts and patients survival at 5 years were compared for liver disease etiology among adults receiving SLK during 2002 and 2011 in the United States. Cox regression analysis models were built to determine the independent impact of liver disease etiology on outcomes. RESULTS: A total of 2,606 patients (mean age 53 years, 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alcoholic liver disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohepatitis (NASH) (n=221), hepatitis B virus (HBV) (n=98), and hepatocellular carcinoma (HCC) (n=249). HCV and NASH+CC contributed to about 44% and 9%, respectively, of all SLK transplants in 2002. Corresponding figures in 2011 were 34% and 22%, respectively. Compared to PBC, 5-year outcomes were worse for NASH, HCV, and HCC for liver graft (72%, 66%, and 72% vs. 82%; hazard ratio, HR: 2.5-3.1), kidney graft (71%, 65%, and 71% vs. 80%; HR: 2.3-2.8), and patient survival (74%, 69%, and 69% vs. 82%; HR: 2.4-2.7). Follow-up renal function assessed at 1, 3, and 5 years showed poor renal function among patients receiving SLK for HCV, NASH, CC, and HBV. CONCLUSIONS: Frequency of SLK transplants is increasing among NASH patients. Overall graft and patient outcomes are good. However, SLK for NASH, HCV, and HCC do worse. Strategies are needed to improve outcomes for SLK in HCV and NASH patients.

KW - Graft survival

KW - Liver transplantation

KW - Mortality

KW - SLK

KW - UNOS

UR - http://www.scopus.com/inward/record.url?scp=84904692148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904692148&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000000048

DO - 10.1097/TP.0000000000000048

M3 - Article

C2 - 24621538

AN - SCOPUS:84904692148

VL - 98

SP - 216

EP - 221

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -